New study reveals an adverse event rate 22 times higher than the FDA-approved drug label reports. (Washington, DC): In a first-of-its-kind study, “The Abortion Pill Harms Women”, the Ethics and Public Policy Center (EPPC) reveals that serious adverse events from mifepristone are approximately 22 times more frequent than the Food and Drug Administration (FDA) currently recognizes. The study shows that, following a mifepristone abortion, 10.93 percent of women experience sepsis, infection, hemorrhaging, or another serious or life-threatening adverse event. That is, over one in ten patients experience at least one serious adverse event. The study, authored by Jamie Bryan Hall,...